{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:08:16Z","timestamp":1793725696854,"version":"4.6.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Research & Clinical Practice"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.orcp.2025.03.001","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T09:41:54Z","timestamp":1742895714000},"page":"178-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?"],"prefix":"10.1016","volume":"19","author":[{"given":"Angela","family":"Procacci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0487-7996","authenticated-orcid":false,"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.orcp.2025.03.001_bib1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s44263-024-00095-w","article-title":"Sweetening the deal: an infodemiological study of worldwide interest in semaglutide using Google Trends extended for health application programming interface","volume":"2","author":"Raubenheimer","year":"2024","journal-title":"BMC Glob Public Health"},{"key":"10.1016\/j.orcp.2025.03.001_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.orcp.2025.01.011","article-title":"Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system \u2013 a disproportionality analysis","author":"Azab","year":"2025","journal-title":"Obes Res Clin Pract"},{"key":"10.1016\/j.orcp.2025.03.001_bib4","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf"},{"key":"10.1016\/j.orcp.2025.03.001_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fdsfr.2023.1323057","article-title":"Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems","volume":"3","author":"Cutroneo","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"10.1016\/j.orcp.2025.03.001_bib6","doi-asserted-by":"crossref","unstructured":"Simonsen E., Lund L.C., Ernst M.T., Hjellvik V., Heged\u00fcs L., Hamann S., et al. Use of semaglutide and risk of non-arteritic anterior ischemic optic neuropathy: A Danish\u2013Norwegian cohort study 2024. https:\/\/doi.org\/10.1101\/2024.12.09.24318574.","DOI":"10.1101\/2024.12.09.24318574"},{"key":"10.1016\/j.orcp.2025.03.001_bib7","article-title":"Association between semaglutide and nonarteritic anterior ischemic optic neuropathy","author":"Chou","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.orcp.2025.03.001_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40942-024-00620-x","article-title":"Once-weekly semaglutide doubles the five-year risk of nonarteritic anterior ischemic optic neuropathy in a Danish cohort of 424,152 persons with type 2 diabetes","volume":"10","author":"Grauslund","year":"2024","journal-title":"Int J Retin Vitr"},{"key":"10.1016\/j.orcp.2025.03.001_bib9","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/jamaophthalmol.2024.2296","article-title":"Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide","volume":"142","author":"Hathaway","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.orcp.2025.03.001_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.6058","article-title":"Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide","author":"Katz","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.orcp.2025.03.001_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2024.6555","article-title":"Semaglutide and nonarteritic anterior ischemic optic neuropathy","author":"Cai","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.orcp.2025.03.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2025.02.025","article-title":"The effect of semaglutide and GLP-1 RAs on risk of non-arteritic anterior ischemic optic neuropathy","author":"Abbass","year":"2025","journal-title":"Am J Ophthalmol"}],"container-title":["Obesity Research & Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X25000389?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871403X25000389?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T19:14:49Z","timestamp":1747854889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871403X25000389"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1871403X25000389"],"URL":"https:\/\/doi.org\/10.1016\/j.orcp.2025.03.001","relation":{},"ISSN":["1871-403X"],"issn-type":[{"value":"1871-403X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disproportionality analysis on semaglutide and nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: An emerging pharmacovigilance signal?","name":"articletitle","label":"Article Title"},{"value":"Obesity Research & Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.orcp.2025.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Asia Oceania Association for the Study of Obesity. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}